Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,708 matching trials from the live ClinicalTrials.gov search.
Conditions
Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
Interventions
Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents

NCT00640653
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Abstinence-only HIV/STD risk-reduction intervention, Safer-sex-only HIV/STD risk-reduction intervention, Long comprehensive HIV/STD risk-reduction intervention, Short comprehensive HIV/STD risk-reduction intervention, Health promotion control intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
662 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Worcester, Massachusetts • Minneapolis, Minnesota
Conditions
HIV Infections
Interventions
Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Conditions
HIV-1 Infection
Interventions
Not listed
Lead sponsor
Prema Menezes, PhD, PA-C
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Cervical Cancer, Cervical Precancer
Interventions
Qualitative interviews, Focus groups
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
25 Years and older
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Conditions
HIV-1-infection
Interventions
EBT-101
Biological
Lead sponsor
Excision BioTherapeutics
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • St Louis, Missouri • Camden, New Jersey
Conditions
HIV Infection, Hepatitis B
Interventions
HEPLISAV-B, ENGERIX-B
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

NCT00858962
Conditions
HIV Infection, HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
Interventions
Health Education, Subspecialty clinic referral
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV Infection
Interventions
Vitamin D3 50,000 IU, Vitamin D3 placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
Terminated Phase 2 Interventional Results available

Cardiometabolic Effects of Eplerenone in HIV Infection

NCT02629094
Conditions
Cardiac Steatosis, Hepatic Steatosis
Interventions
Inspra /Eplerenone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Melphalan, Peripheral Blood Stem Cell Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
4
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 1 more
Conditions
HIV Infection, Gastrointestinal Symptoms
Interventions
GanedenBC30, GBI-30, PTA-6086, Placebo
Dietary Supplement · Drug
Lead sponsor
AIDS Healthcare Foundation
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
HIV Infections, Tuberculosis
Interventions
Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
12 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1
Interventions
ABBV-181, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 11 more
Conditions
Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression, HIV Infections
Interventions
Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
HIV Infections
Interventions
Lamivudine, Methotrexate, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Wichita, Kansas + 4 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Dapivirine Vaginal Ring (VR) in Adolescents

NCT02028338
Conditions
Human Immunodeficiency Virus
Interventions
placebo ring, dapivirine ring
Combination Product
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
15 Years to 17 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Aurora, Colorado • Boston, Massachusetts + 3 more
Conditions
Human Immunodeficiency Virus - Type 1
Interventions
Darunavir (DRV), Ritonavir (rtv)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GW433908, ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina